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Mass spectrometryThe biological roles of the matrix metalloproteinases (MMPs) have been traditionally associated with the
degradation and turnover of most of the components of the extracellular matrix (ECM). This functional
misconception has been used for years to explain the involvement of the MMP family in developmental
processes, cell homeostasis and disease, and led to clinical trials of MMP inhibitors for the treatment of
cancer that failed to meet their endpoints and cast a shadow on MMPs as druggable targets. Accumulated
evidence from a great variety of post-trial MMP degradomics studies, ranging from transgenic models to
recent state-of-the-art proteomics screens, is changing the dogma about MMP functions. MMPs regulate cell
behavior through ﬁnely tuned and tightly controlled proteolytic processing of a large variety of signaling
molecules that can also have beneﬁcial effects in disease resolution. Moreover, net proteolytic activity relies
upon direct interactions between the different protease and protease inhibitor families, interconnected in a
complex protease web, with MMPs acting as key nodal components. Such complexity renders simple
interpretation of Mmp knockout mice very difﬁcult. Indeed, the phenotype of these models reveals the
response of a complex system to the loss of one protease rather than necessarily a direct effect of the lack of
functional activity of a protease. Such a shift in the MMP functional paradigm, together with the difﬁculties
associated with current methods of studying proteases this highlights the need for new high content
degradomics approaches to uncover and annotate MMP activities in vivo and identify novel interactions
within the protease web. Integration of these techniques with speciﬁcally designed animal models for ﬁnal
validation should lay the foundations for the development of new inhibitors that speciﬁcally target disease-
related MMPs and/or their upstream effectors that cause deleterious effects in disease, while sparing MMP
functions that are protective.
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It has been almost 50 years since Gross and Lapiere reported an
interesting collagenolytic activity present during metamorphosis in
tadpoles [1]. The discovery of amphibian interstitial collagenase was
the cornerstone for the eventual description of a large family of
clinically relevant endopeptidases in man, later called matrix
metalloproteinases (MMPs). Further studies then showed that
beyond their collagen-degrading functions, MMPs degrade and
process many other components of the extracellular matrix (ECM),
including the basement membrane, and so were thought to be
important for tumour spread and angiogenesis [2,3]. The ECM is a
complex mesh of structural and signaling molecules that provides
dynamic support to cells and tissues as well as harboring embedded
information that modulates cell behavior [4,5]. Although high-
throughput comprehensive MMP substrate discovery screens have
only just begun and themost recently discoveredMMPs have yet to be
analyzed for their substrate speciﬁcities, it is generally stated that
every component of the ECM can be cleaved by one or more of the 23
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consider that the functional restriction for MMPs as mere ECM
degradative enzymes has greatly stymied the unbiased examination
of MMP activities in vivo for other, potentially more important,
biological roles.
Numerous reports have shown that MMPs are directly implicated
in almost every biological process involving matrix remodeling
throughout the mammalian life span, from embryo implantation [6]
to cell death or necrosis [7,8]. But at what level is their role? For
instance, MMP-driven proteolysis has been linked to several mor-
phogenetic events during development, including mammary gland
ductal branching, bone ossiﬁcation and blood vessel remodeling [5,9].
As well, MMPs play a primary role in normal tissue maintenance
functions, including wound healing and repair, menstruation and
reproductive processes, and innate immune defense [10–20]. As a
consequence, altered expression and/or misregulation of MMP
activities in vivo has been associated with the development of a
wide range of pathologies, including chronic inﬂammatory diseases
and cancer. In all these functions, the conventional dogma still insists
that MMPs participate in these pleiotropic functions primarily
through degradation of the ECM. Although such statements have
been softened with evidence that the loss of ECM scaffold molecules
can lead to the consequent release of a small number of bound growth
factors and exposure of cryptic neoproteins such as endostatin and
angiostatin [21–24] to regulate cell function [4,5]. In contrast
proteomic and yeast two-hybrid screens for MMP substrates and
other recent data have shown more complex roles for MMPs in the
direct regulation of a host of signaling molecules, including most and
likely all of the 54 chemokines inman, and hence the function of many
cells of the stroma and innate immune system [25,26]. An important
theme is also emerging that a key role of MMPs is to mobilize growth
factors, not so much by release from degradedmatrix, but by cleavage
and release of cytokine masking carrier proteins that block growth
factor function and activity [27,28]. These premises will underpin our
review of MMP substrates and biological roles in vivo, in health and
disease.
2. MMPs as key regulators of cell behavior and signaling pathways
2.1. MMP inhibition and failure of clinical trials. A paradigm shift for
MMP functions
The physiological relevance of MMPs is highlighted by the direct
relationship between altered MMP expression and disease develop-
ment. Upregulation of MMPs in diverse important human pathologies,
like cardiovascular diseases, rheumatoid arthritis, neurological dis-
orders and cancer, prompted an early interest in the therapeutic
potential of MMP inhibitors [7,29–33], but without considering the
possibility that some MMP functions may be beneﬁcial and hence
those MMPs may be drug anti-targets [26]. The strong correlation
betweenMMP overexpression and late-stage tumour progression and
metastasis–usually associated with poor clinical outcome–has been
reported as a common feature in transgenic and knockout cancer
animal models, as well as in human tumour samples [7,26,33]. Hence,
it was naturally assumed that such overexpression is causal or at least
important in the progression of the disease. With the recent
recognition that many MMPs are in fact protective in cancer,
performing essential host functions aimed at mitigating the disease,
this concept of elevated expression of a gene product being always
associated with worsened disease outcome is discredited [26].
However, 25 years ago, it was reasonably assumed that connective
tissue breakdown after extracellular and pericellular proteolysis by
tumour and stromal secreted MMPs provided access to the vascular
and lymphatic systems, promoting cell migration, dissemination and
metastasis. This driving hypothesis was the basis for a large number of
clinical trials for MMP inhibitors (MMPIs) as anticancer agents withsome drugs progressing to phase III [26,33]. Unexpectedly, therewas a
global failure in meeting the predicted endpoints of increased life
expectation. At best, the use of high concentrations of the peptido-
mimetic inhibitor Marimastat achieved similar levels of survival to
conventional therapy, itself an accomplishment, but one that did not
allow for declaration of clinical success [34]. Certain MMPIs generated
side effects like musculosketetal pain related to inﬂammation, while
others even showed reduced survival rates for the patients receiving
the MMPI compared to those treated with placebo [35]. Such
disappointing outcomes resulted in the termination of most MMPI
trials and prompted a reevaluation of the role of MMPs as relevant
effectors of late cancer progression, invasion and metastasis. How-
ever, it has been generally overlooked that anti-MMP treatments
showed little or no phenotypic effects that could be attributed to
prevention of normal connective tissue degradation. This is an important
consideration indeﬁning the actual roles forMMPs in vivo. In concordance
with the observations from the MMPI clinical trials, and with the
exception of theMmp14-knockoutmice,most of themodels showedmild
phenotypic alterations with very little matrix remodeling defects. This
indicates thatMMPs–with the exception ofMMP-14which seems to be a
major player in the extracellular fragmentation of collagen [36,37] and
phagocytosis of collagen [38]–might not play such an essential role in
ECM degradation and turnover as originally thought [2–5], a task that
could be carried out by cathepsins via the lysosomal degradationpathway
of phagocytosed collagen [39–41].
With hindsight, it seems clear that burdened with ignorance about
the actual substrates of MMPs and hence their physiological functions
[7,33,42], the MMPI trials were highly likely to fail. In addition,
contributing factors to their failure included the treatment of late
stage tumours only and the use of broad-spectrum MMPIs that also
inhibit close-related metalloproteinases like the ADAMs (a disintegrin
and metalloproteinase) and ADAMTSs (ADAMswith thrombospondin
domains) [43,44].
The paradigm shift for MMP functions, from destructive enzymes
to cell signaling regulators [25] and disease anti-targets [45] also
suggests that the roles of MMPs in disease development are far more
complex than originally thought. Hence, in cancer, MMP activities are
probably more relevant during the early stages of tumour develop-
ment, withMMP-dependent signalingmore relevant biologically than
ECM degradation. The identiﬁcation of chemokine cleavage and the
conversion of chemokine agonists to antagonists by MMPs [15] was
the ﬁrst anti-inﬂammatory role identiﬁed for MMPs. Other MMP anti-
inﬂammatory activities that can be beneﬁcial in disease resolution
include the release of antiapoptotic or antiangiogenic epitopes from
ECM, that also would be blocked by the use of broad-spectrumMMPIs
[26]. Moreover, following the identiﬁcation ofMMP-8 as a cancer anti-
target [45], MMPs-3, -9, -11, -12 and -19 have also been shown to play
protective roles [46,47]. Thus, targeting proteases that are not
effectors of pathology could generate secondary effects or worsening
of the disease upon alteration of MMP-regulated pathways that can be
either beneﬁcial or essential.
Describing the substrate degradome of individual MMPs is one key
to drug target validation that may ultimately lead to new clinical
trials, in which altered deleterious MMP activity–the MMP targets–
and host-protective MMP activity, the antitargets, are clearly deﬁned
so reﬁning the rational development of speciﬁc new MMPIs.
2.2. Proteomics and pharmacoproteomics approaches to
substrate discovery
Degradomics, the proteomics analysis of proteases, their sub-
strates and inhibitors [48], is revolutionizing the understanding of
protease function in vivo by revealing their substrate repertoire, also
called the substrate degradome, and their interaction partners, the
interactome [49]. Indeed, without knowledge of substrates, the
biological roles of proteases can only be guessed. In addition to the
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studies of MMPs have been complemented by the generation of many
animal models based on genetic gain or loss of MMP function and by
new high content analyses designed to unravel the complexity of
MMP functions in vivo.
In the ﬁrst application of the yeast two-hybrid system to ﬁnd
extracellular protein interactors [15] protease substrates were
discovered using “Exosite Scanning” in which the MMP-2 carboxy-
terminal hemopexin domain was used as bait. This led to the
identiﬁcation of the chemokines as a novel group of MMP substrates
so establishing a direct role for MMPs, not just as effectors, but also as
regulators of inﬂammation [14,15,17]. Scanning of peptide libraries
was also used to identify cleavage-site motifs for six MMPs and to
predict MMP substrates based on the preferred cleavage-site motifs
identiﬁed [50]. However, despite the success of these two techniques,
the number of substrates identiﬁed was low and the time consuming
nature of these methods reduced their feasibility for widespread use
to elucidate all MMP substrate degradomes. Such in vitro screens also
have the added disadvantage of analyzing the proteinase or domains
thereof in isolation, thus ignoring interactions with other molecules in
the cellular or tissue context, that are critical for proteinase function,
substrate access and cleavage [51].
New rapid techniques that could identify and quantify proteinase
substrates in more complex biological samples and on a system-wide
basis were required. These came with the development of quantita-
tive mass-spectrometry (MS) based proteomic techniques such as
isotope-coded afﬁnity tag (ICAT) labeling [52]. ICAT labeling involves
differential tagging by reductive alkylation of proteins containing
cysteine residues with chemically identical biotin-tags that differ in
isotopic composition and therefore mass. This allows MS quantiﬁca-
tion of the relative abundance of the labeled proteins within two
samples. ICAT was used in a cell-based substrate discovery screen of
MMP-14 and led to the identiﬁcation of fourteen novel MMP-14
candidate substrates, only two of which were ECM proteins [53]. The
remaining proteins encompassed cytokines, chemokines, cell recep-
tors and serine proteinase inhibitors. A similar approach was used to
examine the effect of the MMP inhibitor Prinomastat on MMP-14
expressing MDA-MB-231 cells. The membrane and secreted pro-
teomes of cells were analyzed giving insight into the effect of both
MMP-14 and Prinomastat on cell membrane ectodomain shedding.
Over twenty-ﬁve known MMP and MMP-14 substrates were
identiﬁed validating the technique, as well as over forty novel
substrates with diverse functions, twenty of which were biochemi-
cally validated in the same study [27]. ICAT analysis has proven to be a
powerful tool for revealing new functions for MMPs in processes such
as angiogenesis. Aside from facilitating angiogenesis through ECM
degradation, identiﬁcation of novel MMP-2 substrates uncovered the
role of MMP-2 in the proteolytic release of proangiogenic vascular
endothelial growth factor (VEGF) from inhibitory complexes with
connective tissue growth factor (CTGF) and Heparin Afﬁn Regulatory
Peptide (HARP) that led to stimulation of neovascularization [28]. The
main disadvantage of ICAT is that only proteins containing cysteines
are analyzed and the number of cysteine containing peptides per
protein is limited, reducing the conﬁdence of protein identiﬁcation
and quantiﬁcation. To circumvent these problems, an alternative
labeling approach, isotope tags for relative and absolute quantiﬁcation
(iTRAQ) was developed [54]. In iTRAQ analysis, proteins from
complex biological samples are digested with trypsin and free-amines
are labeled with isobaric tags, thus ensuring that all proteins within
the sample can potentially be represented and also improving the
peptide coverage of those proteins. Tandemmass-spectrometry (MS/
MS) analysis provides both sequence identiﬁcation of peptides and
quantiﬁcation via the unique mass signature of the tags. An added
advantage of this technique is that there are now eight unique iTRAQ
tags, allowing eight different conditions to be analyzed in a single
experiment. iTRAQ analysis was used to further uncover the diversesubstrate degradome of MMP-2 in a cellular context. With the
increased peptide coverage it was possible to perform “peptide-
mapping” in order to predict the location of cleavage sites within the
native cellular substrate for six of the twenty-three novel MMP-2
substrates identiﬁed [55].
Alternative quantitative proteomic analysis of cell-based MMP
substrate screens includes a label-free technique involving ultraperfor-
mance liquid chromatography electrospray ionization (LC-ESI)-high/
low collision energyMSused to analyze ametastatic prostate cancer cell
line in which MMP-9 expression was knocked-down by RNA inter-
ference [56]. Relative quantiﬁcation between samples was achieved by
comparing peak intensity, with each mass peak deﬁned by exact mass
and retention time (EMRT). Of the twenty novel MMP-9 potential
substrates identiﬁed, only four were ECM related. Interestingly there
was signiﬁcant overlap of potential MMP-9 substrates identiﬁed by this
label-free approach and the MMP substrates identiﬁed by proteomic
techniques using isotope tags. In a second paper for MMP-9 substrates
[57] the proteome of a macrophage cell line over-expressing MMP-9
was compared to control cells and proteins that were selectively
enriched or depleted were identiﬁed by spectral counting, a quantita-
tion technique that is less accurate than isotopic labeling but one that is
readily adaptable to many proteomics laboratories. A peptide mapping
procedure similar to that described before [55] was used to infer
cleavage sites in vivo, however, validation was performed employing
nested synthetic peptides instead of native proteins. This approach
could lead to wrong conclusions, as the exact cleavage sitesmight differ
in the folded protein state. Other proteomic screens for MMP substrates
in complex biologicalﬂuids have utilized 2-dimensional polyacrylamide
gel electrophoresis and in-gel digest. These approaches are easily used
bymany laboratories, but lack throughput and sensitivity and have low
discovery rates. A screen of plasma proteins digested with MMP-14
identiﬁed apolipoproteins thought to play a role in atherosclerosis and
several proteinase inhibitors as substrates [58,59]. Two-dimensional
differential in gel electrophoresis (DIGE) of bronchoalveolar (BAL) ﬂuid
from Mmp2/9−/− mice compared to wild type mice identiﬁed three
MMP substrates that were chemotactic proteins involved in lung
inﬂammation (see below) [60].
The application of these novel approaches to MMP substrate
discovery has greatly accelerated the rate of novel substrate
identiﬁcation, with a diverse range of proteins implicated (Fig. 1).
The following sections summarize the rich catalogue of MMP
substrates recently identiﬁed by degradomics analyses, many through
proteomics-based screens.
2.3. MMP substrates in developmental processes, cellular homeostasis
and disease
2.3.1. Bone remodeling
Skeletal development requires the precisely orchestrated proces-
sing of specialized cartilage and bone matrices through the interplay
of many different cell types. Moreover, once formed, bones still
undergo dynamic tissue remodeling for homeostasis and repair [5]. As
conﬁrmed from the analysis of several MMP knockout mouse models,
MMPs play a major role in bonemetabolism. IndeedMmp14−/−mice,
the only MMP knockout mouse to show a lethal phenotype, have
gross connective tissue and skeletal abnormalities and do not survive
more than 13 weeks postpartum [61,62]. Surprisingly, the loss of
MMP activity resulted in increased bone resorption rather than
increased bone deposition and delayed formation of secondary
ossiﬁcation centers due to impaired vascularization of the hyaline
cartilage, MMP-14 being essential for this angiogenic process, but
with no substrates identiﬁed, the mechanism remains unknown [61].
Osteoblasts from Mmp14-mutant mice showed impaired osteogenic
and collagenolytic activities [61], thus validating the hypothesis
proposed on the basis of in vitro data that MMP-14 is a physiologically
relevant collagenase [63].
Fig. 1. MMP substrates identiﬁed in complex biological samples by proteomic analysis. (A) The diverse range of novel MMP substrates identiﬁed using a variety of proteomic
techniques and (B) Proteins identiﬁed in proteomic screens that were biochemically validated as MMP substrates. The number of proteins identiﬁed or validated for each group is
indicated in parentheses.
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mediating the release and processing of apoptotic and angiogenic
modulators. Mmp9-mutant mice have abnormal expansion of the
zone of hypertrophic chondrocytes caused by delayed apoptosis and
vascularization [64]. Galectin-3, an antiapoptotic lectin that is cleaved
by MMPs-2, -9 and -14 in vitro [65], is enriched in the growth plate of
Mmp9-deﬁcient mice. Indeed, galectin-3-knockout mice show pre-
mature apoptosis of hypertrophic chondrocytes [66], whereas addi-
tion of exogenous full-length galectin-3 phenocopies MMP-9
deﬁciency in culture [67]. Hence, these studies demonstrate regulated
chondrocyte apoptosis in growth plates by speciﬁc MMP-9 processing
of an anti-apoptotic molecule rather than a phenotype due to
perturbed ECM degradation. In addition, recent proteomics screens
have uncovered another member of this family, galectin-1, as an
MMP-2 and MMP-14 substrate [27,55].
The link between MMP-9 and hypertrophic cartilage angiogenesis
was demonstrated upon delayed bone fracture repair in Mmp9-
mutant mice [68]. Loss of MMP-9 activity in the mutant bone cartilage
decreases VEGF bioavailability, resulting in impaired angiogenesis-
dependent remodeling at the fracture site, although the actual
substrate of MMP-9 was not identiﬁed [68]. Based on the ﬁnding
that the closely related protease MMP-2 mobilizes VEGF by cleavage
and release of inhibitory CTGF and HARP carrier proteins [28] from
their complexes with VEGF [69] (Fig. 2), these are likely candidate
substrates that may mechanistically explain these mutant mouse
studies. Similarly,Mmp13-mutant mice also showed expansion of the
zone of hypertrophic chondrocytes, but in this case, MMP-13 function
in the growth plate of long bones seems to be related to the processing
of type II collagen and the proteoglycan aggrecan, which are themajor
components of cartilage at the cartilage-bone interface. In normal
endochondral ossiﬁcation, MMP-9 and MMP-13 might synergistically
cleave aggrecan prior to MMP-13 proteolysis of type II collagen for
proper cartilage-to-bone transition [70,71].
Recently, a pharmacoproteomics screen of MMP-14-transfected
breast cancer cells performed by Butler and colleagues [27] hasuncovered new links between MMP proteolysis and bone metabolism
after the identiﬁcation of the Wnt signaling pathway inhibitor
dickkopf-1 and cysteine-rich motor neuron-1 (CRIM-1) as new
MMP-14 substrates. Dickkopf-1 regulates bone mass through inhibi-
tion of bone formation and induction of resorption and promotes
proliferation and blockage of the differentiation in mesenchymal
stem cells. In disease, dickkopf-1 is strongly related to joint pathology
in rheumatoid arthritis and ankylosing spondylitis, osteolysis in
multiple myeloma and metastatic breast cancer, and bone metastasis
in prostate cancer [72]. On the other hand, CRIM-1 can regulate the
functions of bone morphogenetic proteins (BMPs) by reducing their
effective levels as secreted active growth factors [73]. Further
functional studies are underway to assess the physiological con-
sequences of dickkopf-1 and CRIM-1 proteolytic processing by MMP-
14 in vivo.
2.3.2. Vascular development and angiogenesis
The complex repertoire of signaling functionsmodulated byMMPs
is reﬂected in the way this protease family plays a wide range of pro-
and anti-angiogenic roles in blood vessel development and home-
ostasis. Not surprisingly, deregulated MMP expression and activity is
linked to vascular pathology, such as the previously described defects
in impaired bone remodeling and during tumour angiogenesis.
One of the main mechanisms utilized by MMPs in this process is
the regulation of the bioavailability of angiogenic factors that are
sequestered by the ECM or the basement membrane. Such is the case
of ECM-tethered VEGF, which is mobilized by MMPs-1, -3, -7, -9, -16
and -19 cleavage of the VEGF-binding ECM proteins [68,74,75].
Similarly VEGF forms an inhibitory complex with the heparin-binding
growth factor HARP [69] and is released upon MMP-2 cleavage of
HARP [28] (Fig. 2). In addition, VEGF also forms a latency complex
with a known MMP substrate, CTGF, and MMPs-1, -2, -3, -7 and -13
can release active VEGF from this complex [76] (Fig. 2). In a different
mechanism, VEGF-A transcriptional activation can be speciﬁcally
increased by MMP-14 overexpression. This VEGF-A up-regulation,
Fig. 2. MMPs modulate growth factor functions. CTGF induces secretion of ECM proteins by ﬁbroblasts and associates with VEGF to form a VEGF latency complex. Other
proangiogenic growth factors can be stored in a latent state through interactions with ECM components. When expressed, MMPs can cleave CTGF to eliminate the ECM synthesis
stimulus. The subsequent reduction in matrix deposition can be an alternative MMP-dependent mechanism that has the same outcome as ECM degradation. In addition, MMP
processing can release ECM-tethered growth factors to induce angiogenesis and other cellular functions. By this means, degradation of perlecan renders soluble bFGF; VEGF is
released following proteolytic disruption of the complexes formed with either CTGF, heparin or HARP; TGF-β big latency complex can be solubilized upon cleavage of the LTBP
protein, and further activated by processing of the LAP peptide. Degradation of TGF-β-bound decorin also increases active growth factor levels in the extracellular milieu. Finally,
MMP-shed betaglycan can interact and inactivate circulating TGF-β, thus inhibiting pro-angiogenic processes. Again, whereas MMP activity is suggested to enhance angiogenesis by
basement membrane remodeling, the unmasking of angiogenic factors is another route that also potently increases or blocks angiogenesis. Hence, the importance of MMP activity in
physiological processes traditionally thought to be the result of ECM degradation may in fact be due to other reasons, often representing higher order control of information circuits
that are critical to tissue homeostasis or the process.
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tyrosine kinases-dependent signal transduction pathway [77].
The in vivo relevance of MMP modulation of VEGF bioavailability
was demonstrated by the RIP1-Tag murine pancreatic insulinoma
model. These mice switch on angiogenesis in a discrete step during
cancer progression, despite constitutive expression of VEGF and its
receptors. When RIP1-tag mice were crossed with Mmp9-mutant
mice the angiogenic switch was prevented, showing that VEGF
availability by MMP-9-mediated release is pivotal for the develop-
ment of the angiogenic phenotype [74]. However, in this case, the
release from degraded ECM was thought to account for VEGF
mobilization. Degradation of ECM/basement-membrane by MMPs
can release several other pro-angiogenic factors. Proteolysis of the
heparan-sulfate proteoglycan perlecan by MMP-1 and MMP-3 in
endothelial cells detaches basic ﬁbroblast growth factor (bFGF) [78]
and as discussed in Section 2.3.4, MMPs also release and activatetransforming growth factor -β (TGF-β), another potent proangiogenic
factor (Fig. 2).
Many other processes are included in the functional repertoire of
MMP-dependent control of vascularization and angiogenesis. For
instance, MMP-9 cleaves the cytokine interleukin-8 (CXCL8/IL-8)
[16], enhancing its pro-angiogenic activity tenfold, and degrades the
angiogenesis inhibitor platelet factor-4 [79]. Similarly, MMPs-1, -8,
-13 and -14 also activate CXCL8/IL-8 [19]. During blood vessel
development, MMP-14 plays a regulatory role via proteolytic
processing affecting signaling downstream of the platelet derived
growth factor receptor β (PDGFRβ) [80]. In a very recent paper, the
multifunctional LDL receptor-related protein LRP1 has been uncov-
ered as the link between MMP-14 activity and the platelet derived
growth factor receptor BB (PDGF-BB)-PDGFRβ signaling axis in
vascular smooth muscle cells dedifferentiation, proliferation and
invasion [81].
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MMPs cleave ECM/basement membrane proteins to expose
cryptic sites or to release fragments that act as neo-epitopes. This is
the case of the generation of pro-angiogenic αvβ3 integrin binding
sites upon cleavage of collagen IV by the gelatinases [82,83].
Interestingly, several ECM proteolytic fragments are anti-angiogenic
factors, like endostatin, which is generated upon the cleavage of the
NC1 domain of collagen by different proteases, including MMPs-3, -9,
-12, -13 and -14 [21]. Another angiogenesis inhibitory fragment,
called tumstatin, is a cleavage product from the NC1 domain of the α3
chain of collagen IV. Tumstatin is released upon MMP-9 cleavage in
vitro. Moreover,Mmp9-null mice show decreased levels of circulating
tumstatin associated with an increase in tumour-associated patholo-
gical angiogenesis in a Lewis lung carcinoma model [84]. However,
whether this is due directly to tumstatin is unclear as it is uncertain
whether high enough levels of these fragments can be generated and
maintained to be biologically signiﬁcant. Repression of angiogenesis
can be achieved as well by plasminogen hydrolysis and release of the
potent angiogenesis inhibitor angiostatin by MMPs-2, -7, -9 and -12
[22–24].
The sheddase activities of MMPs can also be linked to either
promotion or inhibition of angiogenesis. Several MMPs are able to
cleave and shed the D1 domain of the urokinase-type plasminogen
activator receptor (uPAR) in vitro [85,86]. In an experimental
angiogenesis model investigating the role of uPAR, inhibition of
MMPs promoted angiogenesis, likely due to an increase in function-
ally available uPAR [87]. On the other hand, by releasing the soluble
ectodomain of the ﬁbroblast growth factor receptor 1 (FGFR1), MMP-
2 abrogates signal transduction even when its FGF binding capacity is
maintained [88]. The shedding of the transmembrane proangiogenic
semaphorin 4D by MMP-14 in head and neck squamous carcinoma
cells induces endothelial cell chemotaxis in vitro and blood vessel
growth in vivo [89].
Lastly, Macotela and colleagues [90] detected MMP-speciﬁc
cleavage of the hormone prolactin in chondrocytes, which releases
a 16-kDa N-terminal fragment that inhibits angiogenesis by blocking
epidermal growth factor (EGF)-induced endothelial cell proliferation.
Interestingly, after hyaline bone formation, cartilage remains an
avascular tissue, and induction of angiogenesis is usually linked
to bone remodeling or tissue destruction in osteoarthritis, thus
reﬂecting the exquisite ability of MMPs to maintain a delicate homeo-
static equilibrium through completely unexpected–and apparently
conﬂicting–activities.
2.3.4. Control of ECM synthesis
MMP-mediated inactivation of the mitogen CTGF results in
impairment of ECM deposition by ﬁbroblasts [91]. Importantly, this
mechanism may represent an alternative pathway regulated by
MMPs that induces phenotypic outcomes resembling connective
tissue degradation [28] (Fig. 2). In addition, another protein closely
related to CTGF, Cyr61 is cleaved by MMP-14 [27]. Cyr61 is a
multifunctional protein that has been reported to promote cell
adhesion, migration, proliferation, differentiation and angiogenesis. It
is also related to ECM deposition and tumourigenesis, and shows dual
cell type-speciﬁc anti- and pro-apoptotic activities [92]. The func-
tional consequences of MMP-14 proteolytic processing of Cyr61 are
unknown, but likely also result in inactivation, modiﬁcation or even
release of free Cyr61, as it binds to integrins and heparan sulfate for
signal transduction [27].
The latent form of transforming growth factor β (TGF-β) can be
sequestered within the matrix through the interaction of its latency-
associated peptide (LAP) and the ECM component latent TGF-β
binding protein (LTBP). Activation of latent TGF-β through cleavage
of LAP (Fig. 2) has been reported for MMPs-2, -9, -13 and -14 [93–95]
and processed LTBPs are consistently revealed in proteomics analysesof MMPs [27,53]. MMP-2 and MMP-3 cleave and release ECM-
tethered LTBP [96,97] and MMPs-2, -3 and -7 degrade the
proteoglycan decorin to release latent TGF-β1 [98]. TGF-β activity
might be also regulated through MMP-14 and/or MMP-16-depen-
dent shedding of the TGF-β-binding betaglycan, a coreceptor that,
when released, can block TGF-β interaction with its signaling
receptors in vitro [99] (Fig. 2).
MMPs participate in elaborate feedback loops in the control of ECM
synthesis and remodeling [3]. Rather than assuming that ECM
degradation accounts for tissue remodeling following MMP expres-
sion and activation, the reduced synthesis of ECM by decapitation of
CTGF anabolic pathways leading to ECM synthesis and accumulation
also results in a similar phenotype but through a different, more
controlled mechanism [49] (Fig. 2). This is ﬁne-tuned and counter-
balanced through TGF-β repression of MMP synthesis and expression,
and further strengthened by the MMP-dependent release of latent
TGF-β and its activation by cleavages in the LAP and LTBP (Fig. 2). On
the other hand, tissue transglutaminase, another MMP substrate, has
been reported to be required for TGF-β activation in some cellular
systems [100]. Transglutaminase is necessary for the crosslinking of
latent TGF-β to the ECM, which promotes TGF-β activation [101].
MMP-dependent degradation of transglutaminase could therefore
reduce this TGF-β activation pathway, as an additional level of control
of ECM synthesis.
Collagen binding to cell surface integrins also upregulates MMP-14
expression [102,103], and so MMP-14 degradation of cellular collagen
would feedback to reduce this integrin-activated expression of MMP-
14, allowing native collagen to accumulate. In this dynamic, MMP-14
degradation of β1-integrin-ligated pericellular collagen would release
proMMP-2 from its type I collagen binding site for activation by MT1-
MMP [104]. Thus, the degradation of cellular collagen would reduce
the integrin-activated expression of MMP-14, allowing native
collagen to accumulate [3]. In these diverse ways, MMPs can maintain
homeostasis of the ECM in the pericellular environment by positively
and negatively regulating the cytokines that control ECM synthesis,
with substrates, such as collagen, controlling the activation and
activity of the MMPs required for their remodeling.2.3.5. MMP substrates in cell migration
MMPs have traditionally been considered as major facilitators of
cellular migration via the breakdown of ECM barriers. However, even
when present, these degrading functions are likely of secondary
importance to more complex, higher order processes that modulate
signal transduction pathways such as proteolysis of extracellular
mediators of cell-ECM or cell-cell adhesion, ectodomain shedding,
receptor cleavage or exposure of cryptic sites leading to cell motility
and invasion. For exampleMMP-2 andMMP-14 cleave the γ2 chain of
laminin-5 to release domain III, exposing a cryptic epitope that
induces epithelial cell migration [105,106]. Laminin-5 γ2 fragment
levels are reduced in the Mmp14-null mouse [107] and it has been
shown that MMPs-3, -8, -12, -13 and -20 can cleave laminin-5 γ2 in
vitro [108]. Another strategy to facilitate cell motility involves
cleavage of adherens junction components. More speciﬁcally, the
transmembrane protein E-cadherin seems to be a primary target for
the MMP-dependent disruption of cell-cell contacts. MMP-7 shedding
of E-cadherin promoted lung epithelium cell migration and repair
[109]. The observed shedding of the 80-kDa soluble ectodomain sE-
cadherin by MMP-3 and MMP-7 facilitated invasion and metastasis in
vitro in a paracrine manner [110,111]. Furthermore, triggering of
signal transduction by concomitant release of β-catenin can exacer-
bate additional proteolysis upon induction of the expression of
MMPs-2, -9 and -14 [112,113]. E-cadherin cleavage by MMPs is also
linked to the induction of the epithelial-to-mesenchymal transition
[110], a transformation associated with aggressive malignant beha-
vior [114]. In addition to E-cadherin, MMP-7 can cleave VE-cadherin,
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culture [115].
Integrins are also pivotal elements for cell adhesion, migration
and invasion. These cell-surface proteins mediate cell-cell and cell-
matrix adhesion and are involved in molecular signaling and
crosstalk processes [87,116]. A controversial paper from the Cheresh
group proposed that MMP-2 binds the αvβ3 integrin through the
hemopexin domain [117]. However, this was later shown to be an
experimental artefact, due to a non-speciﬁc interaction that was only
detected in the presence of BSA-containing ELISA blocking buffer
[118], so casting doubt on other studies [119,120]. Nonetheless, the
MMP-2 activator MMP-14 participates in the proteolytic maturation
of some integrin subunits, such as the components of the αvβ3
integrin. Such processing enhances integrin-mediated signal trans-
duction, leading to increased adhesion and migration on the speciﬁc
αvβ3 ligand vitronectin [120], and regulates crosstalk between
signals that are mediated by different integrins. On the contrary,
tumour-expressed MMP-7 displays an interesting anti-metastatic
activity that is dependent on the cleavage of the β4 subunit, with the
consequent abolition of α6β4 integrin binding to the lung endothelial
protein CLCA2 and the blockage of tumour cell adhesion and
migration [121].
2.3.6. MMP substrates in cellular invasion and metastasis
The transmembrane proteoglycan CD44 binds the hemopexin
domain of MMP-2, as well as for several other MMPs, via its
extracellular portion, locating the proteases at the migrating front
[122-125]. CD44 is an MMP substrate itself, and its proteolytic
processing promotes cell mobility through altered cell adhesion
functions [125,126]. Non-physiological CD44 fragments are often
shed by MMP-14 in malignant tumours, and CD44-mediated anchor-
ing of MMP-2 promotes angiogenesis and invasion by facilitating
localized MMP-2 dependent TGF-β activation [127].
MMP-14 and MMP-16 cleave the transmembrane heparan
sulfate proteoglycan syndecan-1, which has been associated with
inhibition of invasive and migratory properties in the HT1080
ﬁbrosarcoma cell line. MMP-14 is the main candidate for the
observed syndecan-1 ectodomain shedding, which correlates with
the stimulation of cell migration on a collagen matrix [128].
Shedding of the syndecan-3 ectodomain in cultured rat peripheral
nervous system Schwann cells is blocked by various MMP inhibitors,
thus enhancing cell adhesion to collagen. This MMP-dependent
shedding has been also reported to occur in vivo in the peripheral
nerve tissue of newborn rats [129].
The surface-associated tissue transglutaminase is essential for the
maintenance of integrin dependent cell-ECM adhesion and spreading
on ﬁbronectin in both normal and tumour cells. Transglutaminase has
been shown to be cleaved in culture by MMP-2 and MMP-14 and by
MMPs -15 and MMP-16 in vitro [130,131]. Importantly, transgluta-
minase degradation is dependent on MMP-14 overexpression in
glioma and ﬁbrosarcoma cells, and impairs adhesion andmigration on
ﬁbronectin [131]. The biological effects of MMP activities through
transglutaminase appear to be rather complex, as cell mobility in
collagen matrices is increased upon transglutaminase degradation.
Further investigation is needed in order to assess the consequences of
the loss of transglutaminase activities in stroma and cancer cells at
tumour leading edges under different conditions. In addition,
transglutaminase is involved in stabilization of ECM by enzymatic
crosslinking and polymerization of matrix components, making them
resistant to proteolysis and different types of stresses [132]. MMP
cleavage could then regulate ECM stability and rigidity through
controlled transglutaminase inactivation.
The physiological consequences of the degradation of the low-
density lipoprotein receptor-related protein (LRP) are a perfect
example of the pleiotrophic effects that can be derived from targeted
MMP-proteolysis. LRP exerts multiple functions that modulate cellbehavior, either as a cargo protein that mediates endocytosis of a
wide range of ligands including ECM proteins, growth factors and
proteases or as a signal transducer that regulates cell migration
[133]. Several membrane-type MMPs degrade LRP, and the degrada-
tion of this receptor is associated with MMP-14 overexpression in
breast cancer and ﬁbrosarcoma cells [134]. In addition to alterations
in cell signaling, loss of LRP enhances invasiveness by blocking
endocytosis-mediated degradation of several matrix components
and extracellular proteinases, including MMPs-2, -9, -13, urokinase-
and tissue-type plasminogen activators. In this way, MMP-14
overexpression exerts a dual role in tumours by activating extra-
cellular pro-MMP-2 and impeding its clearance [135,136]. Protease
activated receptor 1 (PAR1) is another cell-surface receptor in which
expression levels and transduction pathways are correlated with
metastatic potential in vitro and in vivo. Proteolytic activation of
PAR1 by MMP-1 has been demonstrated in PAR-1-transfected breast
cancer cells, providing an explanation for the reduction in tumour
growth observed in mice treated with MMP-1 speciﬁc inhibitors
[137,138].
During prostate cancer metastasis development in bone, tumour
cells induce the secretion of the transmembrane receptor activator of
the nuclear factor κB ligand (RANKL) by osteoblasts, stromal or other
malignant cells. When in close contact, these RANKL expressing cells
can activate osteoclast-precursor cells via the RANKL receptor RANK.
As a consequence, the activated and differentiated osteoclasts degrade
the bone matrix during metastasis through the expression of several
extracellular proteases. MMP-7 mediated shedding of an active
soluble form of RANKL (sRANKL) into the stroma facilitates this
activation process by eliminating the need for a close cell-to-cell
contact [139]. sRANKL levels and metastasis-related osteolysis were
found to be highly reduced in the tumour-bone interface of Mmp7-
deﬁcient mice when compared with the wild type [140]. Moreover,
MMP-7 might not be the only mediator in these processes, as RANKL
can be also shed by MMP-14 in cell culture [141].
Many other secreted and soluble molecules are subjected to MMP
processing that have the potential to regulate cellular functions, like
the tumour suppressor protein KiSS, which is processed to generate
the soluble decapeptide known as metastin. Metastin is involved in
signaling functions following G-protein coupled receptor binding, and
the ligand activity and anti-migratory effects of metastin in HT1080
ﬁbrosarcoma cells is abolished in anMMP dependent process [142]. In
another example, the blockage of leukocyte chemoattracting CXC
chemokine stromal cell-derived-factor 1 (CXCL12/SDF-1) binding to
its receptor (CXCR4) in breast cancer cells strongly decreases
metastasis to lung and lymph nodes in mice [143]. CXCL12/SDF-1 is
proteolytically inactivated by MMPs-1, -3, -9 and -14 in vitro [14], and
MMPs are proposed to display anti-metastatic properties through
CXCL12/SDF-1 cleavage [7].
The discovery of the signalingmolecule substrates described above
indicates a different role for MMPs in cellular migration–either in
homeostasis or during late cancer stages–one that is much more
complex than previously thought, and demonstrates the need for
improved understanding of MMP biological functions for the
successful use of MMPIs in cancer therapy.
2.3.7. MMP substrates in cell proliferation, tumour growth and apoptosis
The main strategy for MMP control of cell division and prolifera-
tion is based on the regulation of growth factor availability and the
activation or inactivation of growth factor receptors. We have already
described some strategies for the proteolytic release of different ECM-
or cell surface-trapped angiogenic factors, which can also show potent
mitogenic properties, like FGFs or TGF-β. In addition, the physiological
levels of insulin-like growth factors (IGFs) available for receptor
binding and triggering of downstream signaling pathways depend on
the breakdown of a latency complex formed by IGFs and IGF-binding
proteins (IGFBP). MMPs are known to cleave IGFBPs to release active
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cleavage of IGFBP-1 [28,144–146]. The proliferative actions of IGF-1
on smooth muscle cells can be blocked by the expression of an MMP-
resistant IGFBP-5 [147], while degradation of IGFBP-1 by MMP-11
enables IGF-1 dependent growth of breast cancer cells [145]. Recently,
IGFBP-6 has been identiﬁed as a novel MMP-2 substrate in culture by
proteomics analysis [55].
MMP-2 also cleaves the hepatoma-derived growth factor (HDGF),
which shows growth-stimulating activity in ﬁbroblasts, hepatoma
cells, vascular smooth muscle cells, and endothelial cells [148]. Mass-
spectrometry-based peptidemapping analysis suggests thatMMP-2 is
a potential sheddase of HDGF, with part of the full-length molecule
being potentially released from the cell-surface or from heparin-
bound ECM stores [55].
There is evidence that the multiple protease-regulated functions of
heparin-binding epidermal growth factor-like growth factor (HB-EGF)
may be mediated by MMPs. The transmembrane form (mHB-EGF) of
this molecule acts as a juxtacrine growth inhibitor for neighboring cells,
but interestingly, it is converted into a potent paracrine mitogen after
sheddingof the soluble form(sHB-EGF) [149,150]. sHB-EGF ismitogenic
in different cell types [149,151] and is potentially involved in several
important physiological processes, including wound healing, neuroen-
docrine regulation and uterine implantation [149,151]. In cancer, sHB-
EGF accelerates tumour growth rate and induces angiogenesis
[151,152]. mHB-EGF is cleaved by MMP-3 in culture [153] and by
MMPs-2, -9 and -7 in vivo; in the latter case there is an additional
induction of vasoconstriction in mice [150,154].
The cleavage of HARP/pleiotrophin by MMP-2 induces angiogen-
esis through the release of VEGF (see above), but in addition HARP
itself is a chemoattractant and mitogenic protein. The C-terminal
fragment generated upon proteolytic processing of HARP by MMP-2
antagonizes the chemoattractanct and growth promoting activities of
the full-length molecule [28]. Members of the follistatin protein
family have been recently identiﬁed as novel MMP substrates in
system-wide proteomics approaches. MMP-2 has been shown to
cleave follistatin like-1 protein [28,55], a potent pro-inﬂammatory
and pro-angiogenic molecule that also exerts important growth
inhibitory activities in vascular smooth muscle cells and human lung
cancer cell lines [155], thereby suggesting another pro-tumourigenic
mechanism for MMP-2 [28]. The related follistatin-like 3 protein is
cleaved by both MMP-2 and MMP-14 in vitro [27]. Hence, growth
factor binding proteins that mask cytokine activity are proposed to
constitute a major new class of MMP substrates [28].
MMPs-2, -3 and -7 cleave osteopontin [55,156], a multifunctional
small integrin binding ligand N-linked glycoprotein (SIBLING) that is
involved in cell adhesion and migration, wound healing, bone
remodeling or apoptosis. Agnihotri and colleagues [156] have
shown that MMP-3 and MMP-7 processing of osteopontin enhances
its cell adhesive and migratory properties through integrin binding in
vitro. Co-expression of MMPs with osteopontin and detection of
MMP-speciﬁc cleavage products in tumour cell lines and remodeling
tissues in vivo suggests MMP-dependent regulation of osteopontin
activities in wound healing and in tumours. Another SIBLING, bone
sialoprotein (BSP), was recently shown in a critical analysis of its
binding and proMMP-2 activation properties neither to bind nor
activate the enzyme [157], as originally proposed [158].
Tumours have developed many mechanisms, some of them
mediated by MMPs, to block immune cell inﬁltration and evade the
immune response. MMP-9 cleaved the interleukin-2 receptor-α (IL-
2Rα) of T lymphocytes in culture, thus blocking their proliferative
response to IL-2, and MMP degradation of IL-2Rα suppressed the
inﬁltration of tumour-speciﬁc cytotoxic T lymphocytes in vivo [159].
Cleavage ofα1-proteinase inhibitor (α1-PI) byMMPs-1, -3, -7, -8, and
-11 releases a proteolytic fragment that reduces natural killer
cytotoxic effects on tumour cells [160]. MMPs can target different
cytokines and chemokines to modulate inﬂammatory and immuno-logic responses as well (see following section). These mechanisms are
also relevant in the promotion or prevention of leukocyte inﬁltration
into the tumour, but it must be stressed that anti-tumour immune
activities can eventually enhance cancer progression through the
negative effects of chronic inﬂammation, including MMP secretion by
inﬂammatory cells [7].
Evasion of cell death and apoptosis is another successful strategy
used by tumours to promote cell proliferation, division and growth.
MMPs can either trigger or prevent apoptosis by proteolytic
processing of certain signaling molecules. The Fas/Fas ligand (FasL)
signal transduction axis is one of the most important pro-apoptotic
systems affected by MMPs. MMP-3 and MMP-7 can shed the
transmembrane FasL from the cell surface, rendering a soluble FasL
(sFasL) that retains the ability to bind to its receptor, Fas, but that
exhibits lower pro-apoptotic potency [161]. MMP-7-mediated release
of sFasL has different cell-type-speciﬁc outcomes, as it induces
apoptosis in epithelial cells whereas inhibits cell death in tumours
[162,163]. However, MMP-7 also cleaves Fas to inhibit apoptosis in
cancer cells [164].
MMP-14 is responsible for cleaving the ectodomain of death
receptor-6 [53], a transmembrane member of the tumour necrosis
factor (TNF) receptor family that induces cell death by signal
transduction through its cytoplasmic domain [165]. Another mechan-
ism of inhibition of apoptosis is related to the previously described
activation of HB-EGF by MMP-7, which triggers an intracellular
signaling pathway to promote cell survival following interaction of
HB-EGF with the ERBB4 receptor tyrosine kinase [123]. On the
contrary, MMPs can also enhance apoptotic processes through
disruption of cell-cell interactions and subsequent cell rounding,
mediated mainly through the cleavage of cadherins and other
molecules like the platelet endothelial-cell adhesion molecule
(PECAM-1). MMP-dependent proteolysis of the full-length mem-
brane-bound PECAM-1 generates a truncated form that reduces cell-
proliferation and increases apoptosis [166].
2.3.8. MMP substrates in inﬂammation, innate immunity and
wound healing
Inﬂammation is a common process in many pathologies and
during the healing response to injury and infection. Leukocyte
recruitment, a hallmark of inﬂammation, is primarily triggered and
regulated by chemoattractant cytokines known as chemokines. We
have found that precise MMP processing can inactivate, enhance,
antagonize or disperse the chemotactic properties of chemokines,
therefore inﬂuencing the ﬁnal outcome of the inﬂammatory response
and regulating leukocyte homing in homeostasis.
Utilizing a yeast two-hybrid Exosite Scanning screen, McQuibban
et al. [15] ﬁrst identiﬁed the chemokine CCL7/MCP-3 as a novel MMP-
2 substrate, so opening the door to a new ﬁeld of investigation for
MMP biology. MMP-2 cleavage of CCL7/MCP-3 generated an inactive
antagonist molecule that retains the ability to interact with its CCR1,
CCR2 and CCR3 receptors, thus dampening full-length CCL7/MCP-3-
dependent responses in vitro and inﬂammation in vivo [15]. Follow up
experiments showed that this functional shift upon MMP cleavage is
conserved throughout the CC chemokine family, as CCL7/MCP-3,
CCL2/MCP-1, CCL8/MCP-2 and CCL13/MCP4 are also cleaved by
multiple MMPs [15,17,20] (Table 1). Another chemokine, CX3CL1/
fractalkine, which has been described as pro-inﬂammatory in
rheumatoid arthritis [167], is also sequentially cleaved by MMP-2.
After a shedding from the cell membrane, the molecule undergoes N-
terminal processing by MMP-2 to convert a cell surface agonist to a
soluble antagonist that could have protective effects for arthritis and
other disease processes [55]. Hence, MMPs form a negative feedback
loop for controlling macrophage recruitment so suppressing macro-
phage inﬂux and activation in vivo [15].
In neutrophils, the story is reversed. The major polymorpho-
nuclear leukocyte (PMN) chemoattractants are the ELR+ CXC
Table 1
Cleavage of human chemokines by MMPs.
Function Chemokine MMP Comments
Activation CXCL8/IL-8 MMP1, -8, -9, -13, - 14
CXCL5/ENA-78 MMP-1, -8
Inactivation CXCL1/Gro-α MMP-9, -12 Cleaved at E-LR by MMP-12
CXCL2/Gro-β MMP-12 Cleaved at E-LR
CXCL3/Gro-γ MMP-12 Cleaved at E-LR
CXCL8/IL-8 MMP-12 Cleaved at E-LR
CXCL4/PF-4 MMP-9
CXCL7/CTAP-III MMP-9
CXCL11/ITAC MMP-7, -9 MMP-7 degrades the chemokine
CXCL12/SDF-1 MMP-1, -2, -3, -9, - 13, -14 MMP-2-cleaved form is neurotoxic
CXCL5/ENA-78 MMP-9, -12 Cleaved at E-LR by MMP-12, MMP-9 could transiently activate before degradation in vitro.
CXCL9/MIG MMP-7, -8, -9, -12 Cox et al. [177] could not detect previously reported MMP-8, -9 cleavage [172].
CXCL10/IP-10 MMP-7, -8, -9, -12 Cox et al. [177] could not detect previously reported MMP-8, -9 cleavage [172].
CXCL6/GCP-2 MMP-1, -9, -12 MMP-12 cleaves C-terminal to ELR. MMP-1 and -9 degrade the chemokine.
Switch to antagonist CCL2/MCP-1 MMP-1, -3, -8, -12
CCL8/MCP-2 MMP-1, -3, -12
CCL7/MCP-3 MMP-1, -2, -3, -12, - 13, -14
CCL13/MCP-4 MMP-1, -12
CX3CL1/fractalkine MMP-2 Two cleavages, First for shedding, second for conversion.
CXCL11/ITAC MMP-8, -12 Antagonist fragment (5-73) shows enhanced heparin binding. MMP-12 products are
transient followed by degradation in vitro.
No change CXCL6/GCP-2 MMP-8, -9
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exempliﬁed by CXCL8/IL-8 in man and by GCP-2/LIX (LPS induced
CXC chemokine) in the mouse. Interestingly, the neutrophil-speciﬁc
MMP, MMP-8 (also known as collagenase-2), processes the N-
terminus of both CXCL8/IL-8 and GCP-2/LIX upstream of the ELR
motif to enhance chemotactic potency [18,19]. Indeed, MMP-8 null
mice showed impaired recruitment of PMNs in an LPS-induced
inﬂammation model, indicating the high speciﬁcity and relevance of
MMP-8 in the immune response, in this instance by a feed-forward
mechanism for cell recruitment [19]. Notably, MMPs-1, -2, -8, -9, -12,
-13 and -14 also process and activate GCP-2/LIX and/or CXCL8/IL-8 at
the same or nearby sites [18,19] (Table 1). What is critically important
is that in vivo GCP-2/LIX cleavage in the Mmp8−/− mice is not
compensated by the other MMPs that were shown to cleave and
activate GCP-2/LIX in biochemical assays. For instance, MMP-9
cleaves GCP-2/LIX (and CXCL8/IL-8) at the exact same cleavage site
that MMP-8 does with equally good kinetic parameters; in addition, it
is also present in the same PMN secretory granules as MMP-8, and is
even expressed at higher levels than in wild-type mice. Yet, MMP-9
does not compensate for the lack of MMP-8 cleavage and activation of
GCP-2/LIX in vivo [19]. This is not to say that MMP-9 is not involved in
the response, but that it is biologically a minor contribution compared
with the MMP-8 response, despite the similar biochemical para-
meters. Indeed, similar perturbations in PMN chemotaxis have not
been reported for the Mmp9−/− mouse. As found with CXCL8/IL-8,
similar effects were found for another human orthologue of GCP-2/
LIX, CXCL5/ENA-78. The induction of an intracellular calcium inﬂux
and chemotaxis by CXCL8/IL-8 were strongly increased after MMP-8,
-9, -13 and -14 cleavage, akin to theMMP-1 andMMP-8 cleaved forms
of CXCL5/ENA-78 [18]. In addition, CXCL5/ENA-78 is sequentially
cleaved by MMP-9 (Table 1). Initial cleavage by MMP-9 resulted in N-
terminally truncated forms of the chemokine that were 3-8-fold more
active than the full-length molecule, however after prolonged
incubation complete degradation of CXCL5/ENA-78 occurred [18].
Most members of the CXCL chemokine family are inactivated by
proteolysis of their speciﬁc ELR receptor-binding motif by the
macrophage-speciﬁc MMP-12. Such disruption of the interaction of
CXCL1/Gro-α, CXCL2/Gro-β, CXCL3/Gro-γ, CXCL5/ENA-78, CXCL6/
GCP-2 and CXCL8/IL-8 with their receptor has been proposed to
participate in the resolution of LPS-induced inﬂux of PMN leukocytes
by macrophages by taking an active role in this shutting down of theneutrophil response [20]. CXCL1/Gro-α is also inactivated by MMP-9,
like CXCL4/PF-4 and CXCL7/CTAP-III [16]. CXCL9/MIG and CXCL10/
IP-10 are rendered functionally inactive after C-terminal cleavage by
MMP-8 and MMP-9 [168]. During HIV infection, astrocytes over-
express the chemokine CXCL12/SDF-1, which is cleaved at position 4-
5 by CNS macrophage MMP-2, itself activated by neuron derived
MMP-14. The cleaved form of CXCL12/SDF-1 is chemotactically
inactive but highly neurotoxic, and induces neuronal apoptosis and
inﬂammation in mice [169]. This effect was later found to be exerted
through switching receptor speciﬁcity to CXCL3 [170].
In vivo, chemokines are generally immobilized on the ECM or cell
membrane through interactions with glycosaminoglycans (GAGs) to
form temporally and spatially stable haptotactic gradients. MMPs
have the capability to modulate these gradients, either by cleavage
of the proteoglycan core protein [171,172] or by cleaving off the C-
terminal GAG binding motifs from the chemokines themselves so
removing the chemokine-ECM binding properties [173]. For
instance, it has been shown that after bleomycin lung injury,
neutrophils of Mmp7-null mice accumulate in the perivascular
region and are unable to inﬁltrate into the alveolar lumen. It is also
known that, after damage, endothelial cells secrete the neutrophil
chemokine CXCL1/ Gro-α, which is tethered to syndecan-1 after
secretion. MMP-7, secreted by the same cells, cleaves syndecan to
create a syndecan-1-CXCL1/ Gro-α neutrophil chemokine gradient
across the alveolar wall that seems to be essential for neutrophil
invasion of the alveolar space. In Mmp7−/− mice, this gradient
formation is reduced since MMP-7 cleavage of syndecan is lost
[171,172]. Other MMPs shed syndecan-1, like MMPs-14, -16 and -9,
with the latter also cleaving syndecan-4 [128,174]. In contrast, the
human T lymphocyte chemokine CXCL11/ITAC, which signals via
CXCR3, is cleaved at its C-terminal α-helix. This results in loss of
GAG binding and hence causes dispersion of the haptotactic
gradient with concomitant loss of directed T lymphocyte migration
[173]. Collectively, these types of activities appear pivotal for the
establishment, maintenance and resolution of chemokine gradients
during inﬂammatory responses.
Many studies also show the involvement of MMPs in vivo in the
generation of chemotactic gradients. Leukocyte accumulation in the
lung parenchyma of allergen-induced asthmatic Mmp2-null mice is
correlated with a decrease of free CCL11/eotaxin levels [175].Mmp8-
knockout mice showed defective neutrophil recruitment due to
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neutrophils in brochoalveolar lavages of allergen-challenged lungs in
Mmp2 and Mmp2/9-deﬁcient mice correlates with the signiﬁcant
decrease of CCL11/eotaxin, CCL7/MCP-3 and CCL17/TARC levels
[177]. Nevertheless, similar experiments performed with Mmp9-null
mice reported different outcomes, with different cell migration effects
and chemokine levels in both BAL ﬂuids and parenchyma tissues
[178–180], suggesting that regulation of the inﬂammatory response
by MMPs may depend on the nature of the stimulus, and hence the
MMPs expressed. The MMP substrates that mediate these altered
functions in the resolution of inﬂammation remain unknown, but they
are likely pericellular proteoglycans or other ECM-components
involved in chemokine interactions.
The involvement of MMP activities in inﬂammatory responses and
wound healing could explain the beneﬁcial roles played by certain
MMPs. Balbín and colleagues [45] reported the ﬁrst protective
function for an MMP after the observation of increased chemical-
induced skin tumourigenesis in MMP-8-deﬁcient mice. These mice
also showed delayed wound healing, associated with impaired
neutrophil inﬁltration to the injured area [181] and worsened
outcome in arthritis [182]. Interestingly, enhanced inﬂammation
due to neutrophil retention is observed during the last stages of the
healing process at a stage normally characterized by massive
apoptosis of the inﬂammatory cells. Altered SMAD2 activation and
SMAD3 phosphorylation were observed in these mice due to low
levels of circulating TGF-β1, which is also an important pro-
inﬂammatory cytokine with relevant implications in wound healing
[181]. In addition, perturbed generation and dispersion of chemotactic
gradients involved in the resolution of inﬂammation could lead to the
development of chronic inﬂammatory response in arthritis and other
inﬂammatory diseases, and so also to the increased tumourigenesis of
the chemical-induced skin cancer model.
The interaction of MMP activities with chemotactic and inﬂam-
matory processes is not limited to chemokine processing. Several
proinﬂammatory cytokines are also affected by MMP proteolysis.
TNF-α, a potent pro-inﬂammatory cytokine, can be proteolytically
activated by many MMPs in vitro and by MMPs-7, -12, -14 and -17
in cultured cells [53,183,184]. MMP-7 has been shown to activate
TNF-α signaling in a herniated disc culture model to eventually
induce macrophage inﬁltration leading to disc resorption [185].
Another pro-inﬂammatory cytokine, interleukin-1β (IL-1β) is acti-
vated by MMPs-2, -3 and -9, with further incubation driving to
degradation of the mature cytokine, suggesting a tight regulation of
IL-1β activity by MMPs [186,187]. However, these analyses were
performed at very high enzyme to substrate ratios and so it cannot
be assumed that this is a biologically relevant pathway in vivo. Some
reports also suggest alternative regulation of IL-1β functions either
through shedding of its type II IL-1 decoy receptor to generate a
soluble form that interacts and inhibits IL-1β [188], or through
degradation of the receptor [189]. Another example of the relevance
of MMP actions in inﬂammation is the ability of MMP-9 to inactivate
interferon-β [190].
MMP processing of ECM components can also release cleavage
fragments with chemotactic properties. The tripeptide Pro–Gly–Pro
(PGP) is obtained by MMP-9-driven proteolysis of collagen. This
product mimics binding of Glu–Leu–Arg motif-containing ELR+ CXC
chemokines to CXCR1 and 2 and stimulates neutrophil migration
[191]. On the other hand, elastin fragments obtained through MMP-
12 cleavage can drive the inﬂux of macrophages, as observed in a
murine model of emphysema [192]. Even non-ECM proteins like the
MMP-12-cleaved serine protease inhibitor α1-PI can generate
proteolytic products that induce chemoattraction of neutrophils
[193].
MMPs also inﬂuence chemoattraction by non-chemokine sub-
strates by creating gradients with different classes of chemotactic
proteins. In the search for MMP-substrates linked to allergicinﬂammation, Mmp2 and Mmp9-defective mice were compared
with their wild type counterparts after being challenged with an
allergen. Three candidate pro-inﬂammatory proteins identiﬁed
proteomically, Ym1, S100A8 and S100A9 showed further altered
chemoattraction in vitro after being cleaved by MMP-2 and -9. The
reduction of inﬂammatory cell migration into the alveolar space after
blockage of the S100 proteins with speciﬁc antibodies indicates that
MMPs might also inﬂuence the resolution of inﬂammation by
cleavage of S100 proteins [60]. This is also true for the cyclophilin B
or peptidyl-prolyl isomerase, an intracellular protein that is exported
to the cell surface and mobilized by MMPs via heparan sulfate
proteglycan cleavage. Release of cyclophilin B from chondrocytes by
MMPs-1, -2, -3, -9 and -13, induces chemotaxis in human neutrophils
and T cells [194]. In addition, cyclophilin A was recently found to be
cleaved by MMP-14 in cultured MDA-MB-213 breast cancer cells,
likely resulting in release from its tethering interaction with heparan
sulphate glycosaminoglycans, but through a different MMP-depen-
dent mechanism than cyclophilin B [27]. MMPs can participate in
inﬂammatory cell trafﬁcking into damaged tissues through non-
chemotactic signaling pathways. MMP-2 cleaves big endothelin-1
(ET-1) to produce an active peptide that binds to the neutrophil
receptor endothelin A and triggers the MAP kinases (MAPK) pathway
to participate in the transition from adhesive to migratory stage in
endothelial cells [195].
MMP release of signaling molecules can also impact the immune
response via the mobilization of hematopoietic progenitor cells from
the bone marrow as ﬁrst proposed for MMP-9 cleavage of CXCL12/
SDF [14]. Several MMPs including MMP-9, which is stimulated by
macrophage colony-stimulating factor (GMCSF) and granulocyte
colony-stimulating factor (GCSF) in bonemarrow stromal cells, cleave
and inactivate CXCL12/SDF-1 at position 4–5. So, by transiently
reducing the bone marrow hematopoietic cell retention signal,
McQuibban and colleagues [14] proposed that this is the mechanism
for mobilization of stem cells, rather than by MMP-9 cleavage of
basement membrane components. MMP-9 also promoted shedding of
the membrane-associated kit-ligand (also termed stem cell factor)
following the activation of a VEGF receptor-1 (VEGFR1)-dependent
signaling pathway [196]. Proteolytic processing by MMPs is also
involved in pathogen-induced innate immunologic responses. For
exampleMMP-7 activates the bactericidalα-defensins cryptdin-1 and
-4 in the murine intestinal Paneth cells [197,198]. In contrast, MMP-1
and MMP-14 cleave the multifunctional protein pentraxin-3 [27],
which is involved in pro-inﬂammatory response and protection
against bacterial infections [199].
MMPs have developed many precise and non-degradative ways to
modulate the inﬂammatory and immune responses via tight proteo-
lytic modiﬁcation of bioactive mediators that participate in highly
regulated cellular functions. The complete understanding of theMMP-
mediated processes described above–and many others yet to be
discovered–is pivotal for the development of efﬁcient MMPI strate-
gies, thus representing a degradomics challenge for the following
years.
2.3.9. Interactive proteolytic systems. The protease web
MMP biological functions reach another level of complexity when
their interconnections with other proteases are taken into account.
There are more than 560 putative proteases in the human degradome
[48,200] that are responsible for the generation of irreversible (with
the exception of deubiquitination) post-translational modiﬁcations of
every protein [49]. Tight regulation and control of these activities is
achieved through interconnected pathways, ampliﬁcation cascades
and self-regulatory feedback loops that occur within and between
families of proteases. Degradomics data generated by recent high-
throughput proteomics screens has further revealed the depth of the
roles that MMPs play in regulating other classes of proteases and their
inhibitors [27,53,55]. In addition to cleaving other members of their
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[201] or uPA [202], and also many different protease inhibitors like
cystatin C [55], plasma serine protease inhibitor (SLPI) [53], tissue
factor pathway inhibitor [203,204] and several serpins [205–208].
Hence, MMPs can also modulate the net proteolytic potential through
modulation of the activation states of different protease classes. From
a system biology perspective, different protease classes and families
are interconnected in an interactive functional network, termed the
protease web [26,49], with MMPs acting as key nodal proteases. As a
consequence, deregulation or inhibition of an MMP can cause
unexpected pleiotropic effects derived from alteration of other
proteolytic pathways. In the previously described pharmacoproteo-
mics experiment carried out in MDA-MB-231 MMP-14-transfected
cells, quantitative proteomics analyses reported global changes in
protease levels upon inhibition with Prinomastat. Many of the 37
proteases and 10 protease inhibitors identiﬁed in the experiment
showed signiﬁcant changes in level, reﬂecting strong disturbances
along the protease web when MMP activities are blocked [27]. Other
proteases, and mainly the closely related ADAM metalloproteinases,
may also perform some of the signaling functions ascribed to MMPs.
For instance, functional redundancy could exist for the MMP- and
ADAM-mediated ectodomain shedding of molecules like N-, E- and
VE-cadherins [209–211], TNF-α [212–214], CD44 [215], FasL [216] or
EGFR ligands like HB-EGFR [217–222]. These ﬁndings stress the need
for a comprehensive understanding of the underlying mechanisms of
the protease web, in order to predict the consequences of MMP
inhibition for optimal drug development. Indeed, the Kruger lab has
shown that MMPIs can lead to altered protease expression in murine
models of cancer [223–225]. Host overexpression of TIMP-1 induces
an important increase in liver metastasis, partially supported by
upregulation of metastasis-related genes, including several cystein
proteases that enhanced net proteolytic activity in the liver micro-
environment [223]. Interestingly, overexpression of cystatin C did not
reduce TIMP-1-induced metastasis burden and, moreover, induced
expression of plasminogen activators. Further overexpression of
plasminogen activator inhibitor-2 reverted the metastatic phenotype
[224]. The authors propose that excess of circulating TIMP-1 could be
priming liver cells by promoting the formation of a premetastatic
niche. Thus, microenvironmental disturbances of the protease web
that alter gene expression and consequently organ homeostasis can
be responsible for the increase in liver subsceptibility to metastasis
[224].
3. Conclusions and future perspectives
The great number of new substrates discovered for MMPs in the
last few years raises the signiﬁcance of MMPs in regulating many
signaling pathways and hence cell behavior. However, in simple
biochemical experiments where substrates are cleaved by MMPs in
the test tube, careful interpretation is needed. Many substrates
discovered are not cleaved in cell culture or in vivo using mouse
models of disease. This reiterates an important axiom in substrate
discovery and the search for biological roles for proteases: “Just
because it can, does not mean it does” [51]—biochemical evidence
cannot necessarily be translated to cell culture nor to animal models
and certainly not necessarily to man. Nonetheless, Mmp gene
knockout mice show the response of a complex system the loss of
one of its components, and not just the effects of the loss of the
enzyme alone. Hence, interpretation of knockout mice is difﬁcult.
However, what is now clear is that themajority of MMP substrates are
non-matrix molecules and indeedwe propose that a major function of
MMPs is to mobilize growth factors and cytokines—not only by
cleaving the ECM molecules they might be bound to as originally
proposed, but by cleavage and dissociation of cytokine and growth
factor binding proteins such as CTGF, pleotrophin, follistatin and
IGFBPs from their cognate cytokines and growth factors. Thisunmasking of cytokines is likely to be a key new biological role for
MMPs in the control of cell function and homeostasis in many tissues.
The strong association between deregulated MMP activities and
disease development raised great expectations for MMPs as promis-
ing drug targets. The unexpected failure of early clinical trials was
discouraging but this does not justify the total resignation of MMPI
programs, as these trials were designed using incorrect or at least
incomplete assumptions about the actual in vivo functional roles of
MMPs [26,33]. Recent efforts in the degradomics ﬁeld are helping to
understand that MMPs orchestrate highly complex signaling path-
ways through sophisticated proteolytic processing of messenger
molecules and receptors, leaving ECM degradation and remodeling
as a secondary role in homeostasis and disease. Hence, the positive
association between MMP activities and disease development is not
as straightforward as it was assumed before. Now we know that
MMPs can regulate cell proliferation and migration, programmed
death, angiogenesis, immunogenic response and inﬂammation,
tumour growth and several other processes. Further, MMP regula-
tion of other proteases, both directly or indirectly through cleavage
and inactivation of protease inhibitors, renders interpretation of data
from MMPI experiments and Mmp−/− mouse models of disease very
difﬁcult.
From this new perspective, many MMP substrates and functions
remain unknown, particularly for the more recently described MMPs,
necessitating the development of high-throughput, high-content
genomics and proteomics discovery techniques. Deﬁnitive validation
of the new functional activities must then be performed at the
organism level using speciﬁcally designed in vivo animal models. The
achievement of an integrative, system-wide functional annotation of
MMPs and their interactions with the protease web during develop-
ment, homeostasis and disease should lay the foundations for a new
wave of clinical trials, with MMPIs blocking disease related-MMP
targets and/or their downstream effectors, while leaving anti-targets
unaffected for the sake of high efﬁciency and reduced secondary
effects. At least initially, however, these clinical indications will be
limited to short term clinical dosing in order to reduce side effects, but
more particularly, those derived from blockage of MMP anti-targets.
Nonetheless, the importance andwidespread biological roles of MMPs
strongly suggest that MMP deregulation is an important pathogenic
factor in many diseases and so too remains a promising vista for drug
targeting.
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